Literature DB >> 884878

Prevention by somatostatin of rise in blood pressure and plasma renin mediated by beta-receptor stimulation.

J Rosenthal, F Escobar-Jimenez, S Raptis.   

Abstract

The interrelationships of increased plasma renin and elevated blood pressure following acute beta-stimulation by orcipernaline and its prevention by somatostatin was studied in normal man. During somatostatin infusion basal values of renin and blood pressure were unchanged. Following orciprenaline both variables increased significantly. Combination of somatostatin and orciprenaline reduced the rise in plasma renin activity by 49%, mean arterial blood pressure by 21% and heart rate by 19%, compared with beta-stimulation alone. The results indicate that the inhibitory action of somatostatin on plasma renin activity may be mediated via beta-receptors. The lesser increase of blood pressure under somatostatin plus orciprenaline also indicates a possible inhibitory effect of somatostatin on beta-adrenergic receptors.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 884878     DOI: 10.1111/j.1365-2265.1977.tb03329.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

1.  Inhibitory effect of somatostatin on the aldosterone response to angiotensin II: in vitro studies.

Authors:  M Boscaro; C Scaroni; C R Edwards; F Mantero
Journal:  J Endocrinol Invest       Date:  1982 May-Jun       Impact factor: 4.256

2.  Somatostatin reduces gastric mucosal blood flow in normal subjects but not in patients with cirrhosis of the liver.

Authors:  A Sonnenberg; C West
Journal:  Gut       Date:  1983-02       Impact factor: 23.059

3.  Hemodynamic effects of somatostatin in insulin-dependent diabetic subjects.

Authors:  D Giugliano; F Cacciapuoti; M Verza; G Rosato; M Varricchio
Journal:  Acta Diabetol Lat       Date:  1979 Oct-Dec

4.  Conceptualization of a Parasympathetic Endocrine System.

Authors:  Jonathan Gorky; James Schwaber
Journal:  Front Neurosci       Date:  2019-09-23       Impact factor: 4.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.